Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1 chaperone protein, in a mouse model of Alzheimer’s disease: Analyses of administration schedules and combination studies with donepezil and memantine.
Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 ligand ANAVEX 2-73, a novel aminotetrahydrofuran derivative.
Dr. Cameron Durrant Named One of PharmaVOICE’s 100 Most Inspiring People in the Pharmaceutical Industry for 2010
Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs, Regulatory Strategies in Alzheimer’s Disease
Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase I Alzheimer’s Disease Clinical Trials
